- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
European Biotech Targeting Anti-ageing
Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Latest Videos
Latest News
Cytomos Secures £4 Million to Develop Spectroscopy Platform
August 14th 2023
Cytomos will use the £4 million in funding to develop its dielectric spectroscopy technology.
Novartis Finalizes Chinook Therapeutics Acquisition in Deal Worth Up to $3.5 Billion
August 11th 2023
Novartis has completed its acquisition of biopharma company Chinook Therapeutics.
Regeneron Pharmaceuticals to Acquire Decibel Therapeutics
August 10th 2023
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
August 4th 2023
Under a manufacturing agreement, Northway Biotech will develop a manufacturing process for iTolerance’s fusion protein in development for regenerative therapy.
Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion
August 1st 2023
Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.
AstraZeneca and Pfizer Ink $1 Billion Rare Disease Deal
August 1st 2023
AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.
Biovian Invests €50 Million in Manufacturing Facility in Finland
July 28th 2023
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership
July 27th 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
Roche and Alnylam Strike $2.8 Billion RNAi Deal
July 27th 2023
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
Sanofi and Recludix Enter STAT6 Inhibitor Partnership Worth More Than $1.3 Billion
July 24th 2023
Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.